Regeneron Pharmaceuticals (REGN) - Get Report is expected to report quarterly earnings of $5.48 a share on sales of $1.8 billion before the market opens on Tuesday, based on a FactSet survey of 19 analysts.
In the same period a year ago, the company posted earnings of $4.67 a share on sales of $1.5 billion.
The stock has fallen 17.1% since the company last reported earnings on Feb. 6.
Quarterly estimates have risen 8.6 cents a share in the past month.
Regeneron Pharmaceuticals is currently trading at a price-to-forward-earnings ratio of 14.2 based on the 12-month estimates of 22 analysts surveyed by FactSet.
Regeneron Pharmaceuticals is a component of the Real Money Post Industrial Average. Learn more about this and other Real Money premium investing products here.
Jim Cramer and the Action Alerts Plus team are watching the biotechnology sector. To find out more about what stocks they like in the industry click here now to get more from Action Alerts PLUS.
Introducing TheStreet Courses: Financial titans Jim Cramer and Robert Powell are bringing their market savvy and investing strategies to you. Learn how to create tax-efficient income, avoid top mistakes, reduce risk and more. With our courses, you will have the tools and knowledge needed to achieve your financial goals. Learn more about TheStreet Courses on investing and personal finance here.